Molecular Pharmacology Program

The Richard Kolesnick Lab

Research

Pictured: Richard Kolesnick
Richard N. Kolesnick, MD

Our laboratory focuses on the role of sphingolipid signaling as a stress response. In this pathway, generation of the second messenger ceramide in response to diverse environmental and pharmacologic stresses (heat, ionizing radiation, ultraviolet light, chemotherapeutic agents, oxidative challenges, etc.) occurs either by degradation of sphingomyelin or by de novo synthesis. The quality and quantity of the ceramide response, in combination with other signals, determines whether adaptation or apoptosis ensues. This pathway is evolutionarily conserved and is obligate for the heat shock response in yeast.

View Lab Overview

Research Projects

Richard Kolesnick Lab Group

Publications Highlights

View All Publications

People

Pictured: Richard Kolesnick

Richard N. Kolesnick, MD

  • Physician-scientist Richard Kolesnick studies the role of ceramide signaling in radiation-induced vascular dysfunction and tumor regression.
  • MD, University of Chicago School of Medicine
[email protected]
Email Address
646-888-2174
Office Phone
View physician profile
Physician profile

Members

Jin Cheng
Visiting Research Scientist
Regina Feldman, MD
Senior Research Technician
Sahra Bodo, PhD
Research Fellow
Research Fellow
Charles Ferranti
Research Fellow
Aditya Ganju, PhD
Research Fellow
Kuo Shun Hsu, PhD
Research Fellow
Stefan Klingler, PhD
Research Fellow
Christy Li
Graduate Student
SKI Administrative Assistant
Tambudzai Shamu, MPhil
Laboratory Manager
Liyang Zhao
Research Fellow

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Richard N. Kolesnick discloses the following relationships and financial interests:

  • Ceramedix
    Equity; Intellectual Property Rights

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures